Literature DB >> 6969757

Fc fragment activation of T lymphocytes. I. Fc fragments trigger Lyt 1+23- T lymphocytes to release a helper T cell-replacing activity.

M L Thoman, E L Morgan, W O Weigle.   

Abstract

Fc fragments of human IgG stimulate both proliferation and polyclonal antibody formation by B lymphocytes. T lymphocytes, although not proliferating in response to Fc fragments, are triggered to produce a T cell-replacing factor, which substitutes for T cells in the Fc fragment-induced polyclonal response. The factor is produced within 24 hr after Fc stimulation. Neither Fab fragments nor whole IgG have the capacity to stimulate the release of this activity. This material is a product of Lyt 1+23-, Ia-T lymphocytes and requires Ia+ adherent accessory cells for production. The role of the accessory cell is to process the Fc fragments to biologically active 14,000-daltons subfragments, which directly trigger T cells to factor production. This material has been called (Fc)TRF to distinguish it from other T cell factors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6969757

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Effect of rheumatoid factors and normal human sera on immune complex-Fc gamma R interaction.

Authors:  M A Isturiz; M Giordano; G P Serebrinsky
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

2.  Isolation and identification of a biologically active peptide derived from the CH3 domain of human IgG1.

Authors:  E L Morgan; T E Hugli; W O Weigle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

3.  Potentiation of specific human in vitro immune responses by the Fc portion of human immunoglobulin.

Authors:  E L Morgan; W O Weigle
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

4.  Multiple infusions of human intravenous immunoglobulin in chimpanzees do not lead to immune elimination.

Authors:  H Leibl; H M Wolf; G Eder; J W Mannhalter; M M Eibl
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

5.  Reversal of immune complex inhibition of antibody-dependent cell-mediated cytotoxicity by normal human serum.

Authors:  M A Isturiz; S B Fink; M M de Bracco
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

6.  Spontaneous and aggregated IgG induced rheumatoid factor producing cells in rheumatoid arthritis.

Authors:  E J Pisko; R A Turner; M Panetti; S L Foster; E Heise
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

7.  Enhancement of T lymphocyte functions by Fc fragments of immunoglobulins. I. Augmentation of allogeneic mixed lymphocyte culture reactions requires I-A- or I-B-subregion differences between effector and stimulator cell populations.

Authors:  E L Morgan; M L Thoman; W O Weigle
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

8.  Polyclonal activation of human B lymphocytes by Fc fragments. I. Characterization of the cellular requirements for Fc fragment-mediated polyclonal antibody secretion by human peripheral blood B lymphocytes.

Authors:  E L Morgan; W O Weigle
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

9.  Synthetic Fc peptide-mediated regulation of the immune response. I. Characterization of the immunomodulating properties of a synthetic 23-amino acid peptide derived from the sequence of the CH3 domain of human IgG1.

Authors:  E L Morgan; J E Shields; C S Campbell; R L Barton; G A Koppel; W O Weigle
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses.

Authors:  E L Morgan; W O Weigle; T E Hugli
Journal:  J Exp Med       Date:  1982-05-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.